Skip to Content
PR Newswire

CurePSP's clinical guide to rare neurodegenerative conditions is published by leading neurology journal

CurePSP's clinical guide to rare neurodegenerative conditions is published by leading neurology journal

CurePSP's clinical guide to rare neurodegenerative conditions is published by leading neurology journal

Teams from the foundation's Centers of Care compile the definitive guide to patient care

PR Newswire

NEW YORK, July 1, 2021

NEW YORK, July 1, 2021 /PRNewswire/ -- Frontiers in Neurology today published a groundbreaking guide to best practices in the clinical management of progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) created under the auspices of CurePSP by the directors of its 25 Centers of Care and collaborators from their institutions.

Frontiers in Neurology is a leading journal in its field, publishing rigorously peer-reviewed articles across a wide spectrum of basic, translational, and clinical research intended to help improve patient care.

PSP and CBS are rare brain conditions with a relentless course, each usually starting in the mid-60s and leading to death in an average of seven years.  CBS is the most common symptomatic manifestation of the disease called corticobasal degeneration (CBD).  Most physicians, including many neurologists, are reluctant to care for patients with these conditions because of unfamiliarity with their multiplicity of complex, interacting, and debilitating symptoms. While there is as yet no specific or disease-modifying treatment for PSP or CBS, their symptoms are responsive to a variety of medication and nonmedication treatment strategies.

The guide was drafted by 37 top clinicians supervised by a steering committee comprising Lawrence I. Golbe, MD, emeritus professor of neurology at Rutgers University and CurePSP's Director of Clinical Affairs, and three other specialists: Irene Litvan, MD, of the University of California, San Diego; Alexander Y. Pantelyat, MD, of The Johns Hopkins Hospital; and Brent Bluett, MD, of Stanford University. Dr. Golbe said, "As rare and complex diseases with no cures as yet, PSP and CBD have become 'orphaned' in the minds of many clinicians. This paper details the symptomatic management of these diseases and should help physicians and other clinicians become more familiar with these conditions and deliver the best possible care to patients."

CurePSP's Centers of Care are designated for their superior capabilities in caring for people with these "prime of life" neurodegenerative disorders, so named because they tend to strike younger in life than the more-familiar and far-more-common Alzheimer's disease. The steering committee divided the subject into 12 areas, assigning each to its own writing committees composed of the Centers of Care site directors, all neurologists specializing in movement disorders or behavioral neurology, assisted by other clinicians from their institutions.  The steering committee then collated and edited the contributions and submitted the resulting draft to all 37 contributors for further suggestions.

The guide can be found at https://www.frontiersin.org/articles/10.3389/fneur.2021.694872/full

About CurePSP

CurePSP is the nonprofit advocacy organization focused on progressive supranuclear palsy, corticobasal degeneration, and other prime of life neurodegenerative diseases, a spectrum of fatal brain disorders that often strike during a person's most productive and rewarding years. Currently, there is no effective treatment or cure for these diseases, which affect more than 150,000 people in the U.S. alone. Since it was founded in 1990, CurePSP has funded nearly 200 research studies and is the leading source of information and support for patients and their families, other caregivers, researchers and doctors, and allied healthcare professionals. CurePSP is based in New York City. Please visit www.curepsp.org for more information.

Contact:

David Kemp 
President 
802-734-1185 
kemp@curepsp.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/curepsps-clinical-guide-to-rare-neurodegenerative-conditions-is-published-by-leading-neurology-journal-301324452.html

SOURCE CurePSP, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.